SCHEMBL4388111

SCHEMBL4388111

OCCc1sc(-c2ccnc(Nc3ccc(Cl)nc3)n2)nc1O

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SYK P43405 16/20 0.54
ZAP70 P43403 10/20 0.54
SRC P12931 8/20 0.54
CDK2 P24941 6/20 0.40
CDK4 P11802 2/20 0.37
PLK1 P53350 2/20 0.37
CCNT1 O60563 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36
CCNH P51946 1/20 0.36
CCNA1 P78396 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5227039 0.94 SYK (0.54) SYKZAP70SRCCDK2CDK4
SCHEMBL4384008 0.82 SYK (0.48) SYKZAP70SRCCDK2CDK4
SCHEMBL4391924 0.80 SYK (0.43) SYKZAP70SRCCDK2CDK4
SCHEMBL4393948 0.76 CDC7 (0.59) SYKZAP70SRCCDK2
SCHEMBL4388874 0.76 SYK (0.70) SYKZAP70SRCCDK2
SCHEMBL4397546 0.75 CDK2 (0.50) SYKZAP70SRCCDK2CDK4
SCHEMBL5220809 0.75 SYK (0.50) SYKZAP70SRCCDK2CDK4
SCHEMBL4395196 0.75 CDC7 (0.41) SYKZAP70SRCCDK2CDK4
SCHEMBL4385552 0.72 SYK (0.50) SYKZAP70SRCCDK2CDK4
SCHEMBL5036950 0.70 SYK (1.00) SYKZAP70SRCCDK2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP claimed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US claimed
CN-1914199-A Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity CYCLACEL LTD (GB) 2007-02-14 CN claimed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
CN-1914199-A Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity CYCLACEL LTD (GB) 2007-02-14 CN disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318954-A1 Compounds CBR3, NR3C2, NR5A1 SYK 3919/4885ZAP70 3319/4885SRC 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.